An Assessment of Observer Bias in the Shunt Design TrialKestle J.a · Milner R.b · Drake D.c
aDivision of Pediatric Neurosurgery, Primary Children’s Medical Center, University of Utah, Salt Lake City, Utah, USA; bCentre for Clinical Epidemiology and Health Evaluation, Vancouver General Hospital, Vancouver, and cDivision of Neurosurgery, Hospital for Sick Children, Toronto, Canada
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Introduction: An international multicenter randomized trial comparing standard pressure differential valves, Orbis Sigma valves and PS Medical Delta valves, for children with newly diagnosed hydrocephalus failed to show a difference in the time to first shunt failure (power 80%). In order to avoid observer bias, the primary endpoint, shunt failure, was defined by detailed clinical and radiological criteria. Surgeons notified the data center when their patient reached endpoint. Their decision was blindly reviewed by a centralized adjudication process. The current analysis asks: (1) Did the surgeons and the blinded adjudication process agree on the presence of shunt failure? (2) Do the shunt survival curves change when the surgeons’ assessment of outcome is used? Methods: The two methods of outcome assessment (surgeons’ decision and adjudication process) were compared with a kappa statistic for the presence of shunt failure and a log rank statistic for time to shunt failure. Results: The surgeon and the adjudication process agreed on the presence of the primary outcome in 313/344 patients in the trial (kappa = 0.81). The 31 cases of disagreement were evenly distributed among the three shunts. The survival curves generated from the surgeons’ decision were not significantly different from those generated by the adjudication process (log rank = 0.70, p = 0.37) and did not alter the study conclusions. Discussion: Observer bias in the assessment of outcome is always a concern in an unblinded clinical trial such as this one. We did not detect an observer bias of sufficient magnitude to alter the study conclusions.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.